Cited 0 times in

Pembrolizumab plus chemotherapy for advanced gastric cancer – Authors' reply

DC Field Value Language
dc.contributor.author라선영-
dc.date.accessioned2025-02-03T08:48:03Z-
dc.date.available2025-02-03T08:48:03Z-
dc.date.issued2024-02-
dc.identifier.issn1470-2045-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/201876-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherLancet Pub. Group-
dc.relation.isPartOfLANCET ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAntibodies, Monoclonal, Humanized / adverse effects-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols / adverse effects-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung* / drug therapy-
dc.subject.MESHHumans-
dc.subject.MESHLung Neoplasms* / drug therapy-
dc.subject.MESHStomach Neoplasms* / drug therapy-
dc.titlePembrolizumab plus chemotherapy for advanced gastric cancer – Authors' reply-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorSun Young Rha-
dc.contributor.googleauthorSonal Bordia-
dc.identifier.doi10.1016/S1470-2045(24)00022-6-
dc.contributor.localIdA01316-
dc.relation.journalcodeJ02154-
dc.identifier.eissn1474-5488-
dc.identifier.pmid38301694-
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S1470204524000226-
dc.contributor.alternativeNameRha, Sun Young-
dc.contributor.affiliatedAuthor라선영-
dc.citation.volume25-
dc.citation.number2-
dc.citation.startPagee52-
dc.identifier.bibliographicCitationLANCET ONCOLOGY, Vol.25(2) : e52, 2024-02-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.